Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
& `7 P0 H" \' a# v+ W- ?8 {2 Q. u
" c& P: N, j- t# t2 ~" h3 N" `" l* h z$ I+ z v/ }* j, O* o
Sub-category:
9 P' I. W" d: U1 Y5 X! d+ w' SMolecular Targets 7 Y C/ T3 S7 c5 c7 r3 b1 k N
1 e1 M9 G l% W$ h r' p
3 n# M2 z9 ]+ v$ _1 J
Category:
: j; s" \" _4 v- v( K% L; \( CTumor Biology ' L P) b( `* S4 c9 l
) y' Y, m3 \, n1 W8 S" t5 s
2 {; T3 S; u: i4 MMeeting:) t0 A$ n F) d, F
2011 ASCO Annual Meeting
! f% B% b; Z2 C
4 J) H# L) o$ U7 U3 h- Q# x" V- a. A" s3 X7 i9 v- L; T- A* X/ P. ~" Y
Session Type and Session Title:# @0 P' V; W) [# H# i, }
Poster Discussion Session, Tumor Biology
; M$ Y; W, ^6 \8 z2 O, `- S5 i: B& p; h5 t. _6 \0 P
+ I9 y0 G: O4 A& h( u$ u8 S" sAbstract No:
9 N/ K1 l& X* E7 B( [1 H10517
0 G5 J1 t ~* G* ?7 K
1 l: m6 H2 }3 G# h) F) _0 @4 h- T( n8 [1 j/ T" ], P$ p
Citation:
0 s/ M2 J3 e$ IJ Clin Oncol 29: 2011 (suppl; abstr 10517) $ S2 N2 C- e+ y5 l/ [+ ]) t" |
( |3 Y, o3 f7 \# C2 y1 _
7 u: s" d& ~- ~; O& P: p" M8 J' ^Author(s):: b, K: r& V7 m, e4 D# l" Q
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
. Z4 ?' m0 R5 \3 `. P0 i# ]# ]5 @0 w. F
! e, J$ H9 v' u1 T
% i; F, r( s$ w' W. D7 t4 D* ?, M1 b( ]# S; @
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
9 ~2 g+ M6 f4 o- U# Z# T
/ h0 u! h( B7 J& r& R d/ kAbstract Disclosures
+ I- y0 Q$ y" a* I/ k) y* L- K- z# o G' V
0 x, J& S" M: h% T% YAbstract:! ~0 m3 x# S R) K4 K; w* L
2 k c/ x9 i; |3 F: Z' b" S- @" C( W5 D0 B
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.8 B \ Z( R s7 B: i
! t6 c* |) V0 n, a( f( k
4 ?7 d6 S7 t! O& _& C0 n/ V. p8 [3 ] |
跨越十年丨憨叔靶向轮换的感悟及思路
我们在筷子治疗九周年纪念文章《跨越九年丨憨叔靶向轮换传承和发扬 --筷子奥希替尼
母亲晚期肺癌跨越13年，这是我家长期
讲述者：不怕辣椒不怕癌整理者：雪漓
在我家抗癌跨越10年之际，鹰版就曾邀请我写一篇
它是比脑转移预后还差的转移部位，今
作者：闵
肝脏对我们的重要性不言而喻，然而治疗中不仅各种药物会对肝脏造成损伤，就
MATTERHORN III期试验中，与单独化疗
MATTERHORN III期试验中，与单独化疗相比，英飞凡治疗方案将早期胃癌患者死亡风险降低
DESTINY-Breast11 III期临床研究
DESTINY-Breast11 III期临床研究：优赫得序贯THP方案术前治疗，使高风险HER2阳性早期
`0 N* ]$ ?, L! K1 N% R
显身卡
